Fast Company Unveils 2023 List of the World's 10 Most Innovative Biotech Companies

Today, the well-known business media "Fast Company" announced "List of the 10 Most Innovative Biotech Companies Globally”。This list includes newcomers who have made remarkable breakthroughs in technologies such as DNA sequencing and cell isolation, as well as several innovative companies aiming to improve existing CAR-T and gene-editing therapies and optimize current drug development processes.These selected companies represent the vanguard of humanity's journey in pharmaceutical innovation, and the groundbreaking technologies they are developing also indicate potential future directions for the industry.

Ultima Genomics: Breaking the $100 Whole Genome Sequencing Ceiling

Genomic sequencing technology has seen continuous breakthroughs in recent years. In the past decade, the industry has reduced the cost of sequencing each whole genome to 1,000 US dollars. HoweverUltima GenomicsNot satisfied with this, by drawing on methods and materials frequently used in the semiconductor industry—standard silicon wafers,Ultima Genomics' sequencing instruments have reduced the cost of sequencing each sample to around $100 while accelerating sequence read times.！The sequencing instruments developed by Ultima Genomics have been adopted by more than a dozen major research institutions, including the Broad Institute of Harvard and MIT, the New York Genome Center, Baylor College of Medicine, and the Sanger Institute. In addition, Ultima has reached an agreement with Regeneron, which has acquired a portion of the company to help Ultima advance its second-generation sequencer.

10X Genomics: Detecting Gene Activity at Specific Times and Locations

Biology is the science of three-dimensional structures, and the development of 10X Genomics in the field of spatial transcriptomics will help biologists conduct more precise exploration and research within three-dimensional systems.The products developed by 10X Genomics enable ultra-precise localization of gene activity in both time and space, facilitating more effective targeted disease treatment.For example, its innovative Fixed RNA Profiling Kit allows researchers to collect "fixed" tissues or cells for whole transcriptome sequencing. Another product, the Nuclei Isolation Kit, enables single-cell analysis of frozen tissues. The company launched these products in December of last year.The Xenium platform enables in-situ direct sequencing of genes in each cell within tissue or tumor samples, and analyzes the activity of each gene with extremely high resolution.10X Genomics has also partnered with Illumina to integrate its technology with Illumina's sequencers and software, further expanding its technological development into other fields.

DNAnexus: Managing Sequencing Data at the National Level

DNAnexus provides a cloud-based data analysis and management platform for DNA sequencing data. The company currently has over 12,000 users across 48 countries, including seven of the top ten pharmaceutical companies globally and eight of the largest diagnostic developers. In 2022,DNAnexus Collaborates with UK Biobank on Long-Term Research to Launch the World's Largest Whole Exome Sequencing Dataset, Including Detailed Health Information of Corresponding IndividualsThis database will collect data from nearly500,000 British VolunteersThe sample information is intended to be made available to hundreds of companies, non-profit organizations, and researchers worldwide.

Akadeum: Developing Rapid Cell Separation Technology for CAR-T Therapy

CAR-T therapy uses genetically engineered white blood cells to help a patient's immune system fight cancer. However, the first step in this therapy is to separate white blood cells from the patient’s or donor’s blood while maintaining the health of the separated cells. Processing a single sample typically takes several hours, making it a tedious and time-consuming task.Akadeum's buoyancy-based cell separation technology uses microbubbles to accelerate the cell separation process.The Dead Cell Removal Kit, launched by the company in August last year, enables researchers to precisely target, isolate, and remove significant and large numbers of dead cells from samples. Additionally, the Human T Cell Isolation Kit, developed by the company, became available in September last year and is intended for research use.Can reduce the processing time of white blood cells from 3 hours to 1 hour.The company's technology can separate cells, nucleic acids, proteins, or specific chemical substances from biological samples as needed.

iSpecimen: Providing scientists with hard-to-obtain research specimens

Now,Through iSpecimen, researchers can quickly obtain a variety of human blood and tissue samples needed for research. iSpecimen provides a wide range of samples covering various diseases, allowing researchers to bypass the tedious and time-consuming processes traditionally required to acquire biological materials.In April last year, iSpecimen improved its sample search and supplier data integration, allowing researchers to directly search for the required samples within iSpecimen's network through a Google-like search bar. Currently, iSpecimen's services cover 18 countries, with clients including 70% of the top 20 global pharmaceutical companies and 70% of the top 20 in vitro diagnostic companies.

Abcam: ushering in a new era of antibody production

Abcam Focuses on Producing Antibodies for Life Science Research. From Mid-2021 to Mid-2022, the Company Launched Approximately 9,000 New Antibodies, Bringing Its Total Number of Antibody Products to 29,000.The polyclonal antibody launched last year can recognize multiple surface structures of the same antigen, which will help combat viruses with various mutations.Abcam Collaborated with Epic Sciences Last Year to Jointly Develop an Innovative Liquid Biopsy for Prostate Cancer.

Colossal Biosciences：RecoveryAlreadyThe Existence of Extinct Species

The establishment of Colossal, Inc. aims to restore the existence of extinct species. Until now, Colossal has published high-quality genome sequencing results for African and Asian elephants.Becoming the first company to artificially create pluripotent stem cells from African and Asian elephants, as well as long-tailed opossums.Colossal has also established an embryo laboratory for many endangered species, optimizing the process of somatic cell nuclear transfer in elephants. Last year,Colossal Collaborates with the Global Science Alliance's Vertebrate Genomes Project to Genetically Conserve Asian, African, and Forest Elephants through Genome Sequencing.The company also began addressing an urgent issue — researching the mechanism by which elephant endotheliotropic herpesvirus leads to illness and death in juvenile Asian elephants. At the end of January this year, Colossal completed a $150 millionExcess B-round Financing。

Recursion: Removing Human Bias from Drug Discovery

Recursion enhances the capability of novel drug discovery by utilizing machine learning and advanced laboratory automation processes.The company conducts millions of experiments every week to generate biochemical reaction experimental data that can be searched by machines.`, and import these large amounts of data into its large database.`By analyzing these data with powerful supercomputers, the company can make new discoveries or establish new connections, such as pairing molecules with novel disease targets or repurposing an old drug for a new use.This automated approach can also eliminate human biases in the drug discovery process, which often lead scientists to overlook promising research directions or waste too much time on dead ends. In 2022, Recursion initiated clinical trials for four drug candidates in its pipeline. The company has entered into a collaboration with Genentech, receiving an upfront payment totaling $150 million, to jointly identify and develop up to 40 new therapies in the fields of neuroscience and oncology.

Emulate: Develop Organ Chips to Replace Animal Testing

Metagenomi: Identifying Innovative Gene Editing Tools